Hisky Medical

Hisky Medical, originating from Tsinghua University, is committed to becoming a leading enterprise in innovative diagnostic and treatment technology, making significant contributions to human health. The company’s mission is to "Popularize High-end Technology, Protect Public Health." Hisky has developed multiple brands, including the iLivTouch® non-invasive liver diagnostic system, the CelTouch® confocal microprobe imaging system, the EQTouch® ultrasound platform, and breast disease diagnosis and treatment solutions. These products can be applied in non-invasive screening, diagnosis, and post-treatment management across various fields such as hepatology, gastroenterology, physical examination, pulmonology, breast care, urology, and surgery. With a strong R&D foundation, Hisky has participated in numerous national and provincial scientific projects such as the National Twelfth Five-Year Science and Technology Support Plan, the National Thirteenth Five-Year Major Science and Technology Project, and the Beijing Natural Science Foundation Key Project. The company has applied for and obtained over 500 patents worldwide, achieving international standards in advanced optical systems, acoustics, and intelligent imaging. Hisky has received numerous honors, including the Huang Jiasi Biomedical Engineering Award, the Huaxia Medical Science and Technology Award, the Chinese Medical Science and Technology Award, the China Patent Excellence Award, and various provincial and municipal science and technology/innovation awards. Hisky has established facilities in Beijing, Shandong, and Jiangsu, with a business network across the country. At the same time, Hisky has obtained certifications from international markets, including the FDA in the United States, CE in the European Union, PMDA in Japan, TGA in Australia, KFDA in South Korea, and RZN in Russia. The company’s products have been sold in over 60 countries and regions worldwide, serving tens of millions of patients globally.